Drugs · Brain health technique
BPC-157
Evidence grade: Weak

A synthetic peptide (15 amino acids) touted for regenerative, anti-inflammatory, and healing properties. Not FDA-approved for any use.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Emerging Longevity / Neuroregenerative Agents
- Evidence grade
- Weak
The evidence behind BPC-157
The science is very early. A rodent study offers emerging evidence that BPC-157 acts on receptors for two growth factors your body uses to repair tissue. Animal results may not hold in people.
Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science
More Drugs techniques
Pair this with other habits from the same practice.

Evidence grade: Context Dependent
Anti-Amyloid Monoclonal Antibodies
FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™).

Evidence grade: Context Dependent
Antihypertensives
Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

Evidence grade: Context Dependent
GLP-1 Receptor Agonists
A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation.
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.